Erica Campagnaro is a Hematology physician affiliated with University of Michigan. OpenAlex indexes 103 publications with 2,683 citations (h-index 21); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1500 E Medical Center Dr
Ann Arbor, MI 481095000
Telephone
734-936-4000Provider last certified this registry record 2 Jan 2024.
Clinical trials
- Bortezomib, Dexamethasone, and Cyclophosphamide in Treating Older Patients With Multiple Myeloma
Sponsor: Case Comprehensive Cancer Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Tempus AI, IncProgram year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
63.8%Thalidomide Analog57.7%Revlimid61%Pomalyst25%Lenalidomide14%Part D≥106 patientsKinase inhibitor2.3%Brukinsa100%Part D<11 patients+ 2 more classes in this area
Dermatology
11.4%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor11.4%Acyclovir100%Part D≥58 patientsSensory organs
6.3%Corticosteroid6.3%Dexamethasone100%Part D≥39 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Multiple Myeloma, Version 5.2026, NCCN Clinical Practice Guidelines In Oncology
Journal of the National Comprehensive Cancer Network
2026 - NCCN Guidelines® Insights: Multiple Myeloma, Version 1.2025
Journal of the National Comprehensive Cancer Network
2025 - Management recommendations for kidney transplantation in patients with plasma cell dyscrasia
Kidney International
2025 - Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network
2024 - Administration of teclistamab in four patients with multiple myeloma requiring hemodialysis
Journal of Oncology Pharmacy Practice
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Moshe Talpaz, MD
University of Michigan
William Herman, MD
University of Michigan
Max Wicha, MD
University of Michigan
Dinesh Khanna, MD
University of Michigan
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”